Illegal since mid-may, ginkgo biloba extract events cause the public attention again, after the incident wave is still working at present, there are industry declined to be named to netease financial analysts pointed out that although the food agency requirements relevant enterprises should recall drug recall all in place before June 3. , "but for now, the impact of the event can not cease in the short term, or will continue to spread and influence the whole industry".

    National food administration of drug safety after bulletin, guilin xingda pharmaceutical co., LTD. And than bond (hunan) natural products co., LTD., the two companies to reduce costs, illegal will ginkgo biloba extract production process from dilute ethanol extract to 3% hydrochloric acid extraction, produce product of ginkgo biloba extract basic clinical curative effect. State drug supervision administration medicine chemical supervision department Mr Li, after verification, found that 24 bought such products of drug companies, has confirmed that there are some companies use this kind of ginkgo biloba extract product for pharmaceutical production.

    Bulletin shows that guilin xingda pharmaceutical co., LTD. In addition to the ginkgo biloba extract production technology by dilute ethanol extraction to 3% hydrochloric acid extraction, at the same time also never have the qualification of the enterprise purchases by hydrochloric acid process of ginkgo biloba extract, used in the production of ginkgo leaf, and outsourcing of extract sales to other pharmaceutical producing enterprises, forged for raw material purchase parameter and production inspection records.

    It is reported, the involved how for the listed companies in pharmaceutical producing enterprises, Chinese medicine resources including yunnan baiyao group co., LTD., company source medicine and Fang Cheng pharmaceutical and pharmaceutical companies listed in Hong Kong green leaves.

    According to food drug safety bulletin, the pharmaceutical producing enterprises also have problems will products sold to other pharmaceutical production enterprise's behavior, such as yunnan baiyao, according to the announcement, a subsidiary of traditional Chinese medicine resources companies bought illegal ginkgo biloba extract, and the total 6.9 tons of goods sold to yunnan to increase green pharmaceutical co., LTD. Peace branch. And increase of yunnan green pharmaceutical co., LTD. Is a well-known domestic pharmaceutical enterprise kahn's subsidiary. "Chinese medicine resources in response to downstream customers in yunnan TaoAnNing branch to carry out foreign business needs, from with ginkgo biloba extract production qualification of guilin xingda purchase five batch of 6.9 tons of ginkgo biloba extract, and sales to the yunnan TaoAnNing branch, so far, all the goods have been sent to yunnan and TaoAnNing branch".

    In food drug safety administration issued a "comprehensive" make, there have been new company is involved. On May 31st, the administration of state food and drug supervision and administration on its website issued "about further do a good job in ginkgo biloba drug special notice, notice requirements related to enterprise" ensure should be recalled drugs before June 3rd recall all in place ". And as of June 1, the announcement announced to wade "ginkgo biloba extract" products of all kinds of measures of listed companies has reached nine, respectively is thousand source pharmaceutical, Fang Cheng, yunnan baiyao, haiwang biology, kahn bei, Hansen pharmaceutical, yi hundred pharmaceutical, letter states pharmaceutical, etc. , are the industry sources declined to be named to the netease finance pointed out that because of the ginkgo biloba extract production in the current Chinese medicine to generate highly concentrated in the enterprise, with the development of events, more and more enterprises or will be affected. , "the impact of the event is still in the short term can't stop, or will continue to spread and influence the whole industry".

    It is reported, ginkgo biloba extract by Germany developed since 1965, are widely used in the whole world, it is mainly used in neurology, heart, the elderly, regions and health with family. By 2013, the global market of ginkgo leaf preparation (including injection) annual sales of $7 billion, at present our country has 117 ginkgo biloba oral preparations of approval.

    In addition, at present China has become the world's largest producer of ginkgo biloba extract. According to booz, according to the current global ginkgo biloba extract production mainly concentrated in China, Germany and France. In 2013, the above three annual production accounted for 78.3% of global production. Among them, ginkgo biloba extract production in China is 348.6 tons, accounted for 48.52% of global production at the same period; German production of 107.3 tons, 14.93%; The French production of 106.8 tons, accounting for 14.86%.

    According to the national food drug safety administration (CFDA) database data shows that: as of January 2015, domestic production and imports of ginkgo biloba extract 113 production and sales of manufacturers, including injection 13, 100 oral preparations. According to incomplete statistics, the ginkgo processing industrial chain now has more than 300 production and operation of the manufacturers, the main production of ginkgo biloba extract and downstream products, including drugs, health care products, cosmetics, food and beverage, etc. Series of products.